These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 21844318)

  • 1. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.
    Goldstein EJ; Citron DM; Sears P; Babakhani F; Sambol SP; Gerding DN
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5194-9. PubMed ID: 21844318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial activities of fidaxomicin.
    Goldstein EJ; Babakhani F; Citron DM
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S143-8. PubMed ID: 22752863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased cure and increased recurrence rates for Clostridium difficile infection caused by the epidemic C. difficile BI strain.
    Petrella LA; Sambol SP; Cheknis A; Nagaro K; Kean Y; Sears PS; Babakhani F; Johnson S; Gerding DN
    Clin Infect Dis; 2012 Aug; 55(3):351-7. PubMed ID: 22523271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fidaxomicin: in Clostridium difficile infection.
    Duggan ST
    Drugs; 2011 Dec; 71(18):2445-56. PubMed ID: 22141387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults.
    Nelson RL; Suda KJ; Evans CT
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD004610. PubMed ID: 28257555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.
    Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN
    Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.
    Figueroa I; Johnson S; Sambol SP; Goldstein EJ; Citron DM; Gerding DN
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S104-9. PubMed ID: 22752857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
    Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fidaxomicin inhibits spore production in Clostridium difficile.
    Babakhani F; Bouillaut L; Gomez A; Sears P; Nguyen L; Sonenshein AL
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S162-9. PubMed ID: 22752866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
    Cornely OA; Crook DW; Esposito R; Poirier A; Somero MS; Weiss K; Sears P; Gorbach S;
    Lancet Infect Dis; 2012 Apr; 12(4):281-9. PubMed ID: 22321770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. U.S.-Based National Sentinel Surveillance Study for the Epidemiology of Clostridium difficile-Associated Diarrheal Isolates and Their Susceptibility to Fidaxomicin.
    Snydman DR; McDermott LA; Jacobus NV; Thorpe C; Stone S; Jenkins SG; Goldstein EJ; Patel R; Forbes BA; Mirrett S; Johnson S; Gerding DN
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6437-43. PubMed ID: 26239985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.
    Liao CH; Ko WC; Lu JJ; Hsueh PR
    Antimicrob Agents Chemother; 2012 Jul; 56(7):3943-9. PubMed ID: 22508299
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.
    Warren CA; van Opstal EJ; Riggins MS; Li Y; Moore JH; Kolling GL; Guerrant RL; Hoffman PS
    Antimicrob Agents Chemother; 2013 Feb; 57(2):689-96. PubMed ID: 23147742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fidaxomicin: a review of its use in patients with Clostridium difficile infection.
    Scott LJ
    Drugs; 2013 Oct; 73(15):1733-47. PubMed ID: 24136090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan.
    Mikamo H; Tateda K; Yanagihara K; Kusachi S; Takesue Y; Miki T; Oizumi Y; Gamo K; Hashimoto A; Toyoshima J; Kato K
    J Infect Chemother; 2018 Sep; 24(9):744-752. PubMed ID: 29934056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany.
    Watt M; McCrea C; Johal S; Posnett J; Nazir J
    Infection; 2016 Oct; 44(5):599-606. PubMed ID: 27062378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Oral Metronidazole, Vancomycin, and Fidaxomicin on Host Shedding and Environmental Contamination With Clostridioides difficile.
    Turner NA; Warren BG; Gergen-Teague MF; Addison RM; Addison B; Rutala WA; Weber DJ; Sexton DJ; Anderson DJ
    Clin Infect Dis; 2022 Mar; 74(4):648-656. PubMed ID: 34017999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High in vitro activity of fidaxomicin against Clostridium difficile isolates from a university teaching hospital in China.
    Cheng JW; Yang QW; Xiao M; Yu SY; Zhou ML; Kudinha T; Kong F; Liao JW; Xu YC
    J Microbiol Immunol Infect; 2018 Jun; 51(3):411-416. PubMed ID: 28693926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.